Kornimate/medical-research-clean huggingface dataset:
the use of ct to identify damaged heart muscle in patients undergoing ventricular tachycardia ablation.

Conditions: Ventricular Tachycardia

Summary: patients with ventricular tachycardia (vt) undergo catheter ablation. during the ablation procedure, the heart is mapped to determine areas of heart muscle damage. the heart scarring areas are often the source of the vt. delayed enhancement ct has recently been used to determine areas of scarring . this study is to determine if the areas of damaged heart muscle mapped with the delayed enhancement ct correlate with the same areas that are determined during the catheter ablation.

catheter ablation of ventricular tachycardia (vt) is performed in patients who have recurrent vt despite the use of other therapies. electroanatomic mapping of the left ventricular myocardium is performed as part of these procedures to define the arrhythmogenic substrate for subsequent ablation. we hypothesize that delayed enhancement multi-detector computed tomography (mdct) will identify areas of myocardial scarring or fibrosis that correlate with findings of voltage mapping in patients with a prior myocardial infarction who are undergoing vt ablation. we will perform a pilot study involving 10 patients with coronary artery disease scheduled for vt ablation to determine the ability of delayed enhancement mdct to identify arrhythmogenic substrates in these patients, when compared with electroanatomic mapping. all patients will undergo a standard of care 64-slice mdct study, followed 5 minutes later by the research delayed enhancement acquisition. we will evaluate the relationship between hyperenhanced myocardium, as detected by delayed enhancement mdct, and abnormal myocardium detected on voltage mapping, defined as areas of myocardium with \< 0.5 mv signal amplitude. studies will be performed on the new siemens 64-slice dual source ct scanner, which reduces radiation exposure from the scan by 33-50%. this study will generate preliminary data which will be used for subsequent nih/aha grant applications or industry sponsored trials.

Eligibility criteria:
inclusion criteria: * age \> 21 years * prior myocardial infarction * scheduled for ct scan \< 1 week prior to vt ablation for ventricular arrythmia exclusion criteria: * serum creatinine \> 1.8 mg/dl * contrast dye allergy * atrial fibrillation * unable to lie flat for the duration of image acquistion (15-20 minutes) * clinical instability at time of ct study acquisition * women of childbearing potential * personal or social problems that might prevent compliance with the study

Keywords: delayed enhancement computed tomography ventricular tachycardia ablation ventricular tachycardia
prophylactic octreotide to prevent post duodenal emr and ampullectomy bleeding

Conditions: Adenoma

Summary: our hypothesis is that prophylactic administration of 5 days of octreotide following emr or ampullectomy in patients with duodenal and ampullary adenomas greater than or equal to 10mm.

inclusion criteria: duodenal or ampullary adenoma greater than or equal to 10mm. duodenal or ampullary adenoma that is suitable for endoscopic mucosal resection. medically fit for anesthesia, endoscopy, and emr able to provide informed consent 18 years or older, male and female exclusion criteria: duodenal or ampullary adenoma \<10mm duodenal or ampullary adenoma that is not suitable for endoscopic mucosal resection medically unfit for anesthesia, endoscopy, or emr unable to provide informed consent less than 18 years old allergy to octreotide

Eligibility criteria:
inclusion criteria: duodenal or ampullary adenoma greater than or equal to 10mm duodenal or ampullary adenoma that is suitable for endoscopic mucosal resection medically fit for anesthesia, endoscopy, and emr able to provide informed consent 18 years or older, male and female exclusion criteria: duodenal or ampullary adenoma \<10mm duodenal or ampullary adenoma that is not suitable for endoscopic mucosal resection medically unfit for anesthesia, endoscopy, or emr unable to provide informed consent less than 18 years old allergy to octreotide
constraint-induced (ci) movement therapy for progressive multiple sclerosis (ms)

Conditions: Multiple Sclerosis

Summary: this trial will evaluate whether progressive multiple sclerosis associated with hemiparesis may benefit from constraint-induced movement therapy.

constraint-induced movement therapy was developed to treat stroke hemiparesis. due to the similarity between multiple sclerosis and stroke in terms of chronic motor deficit, this trial will attempt to determine whether multiple sclerosis may benefit similarly from constraint-induced movement therapy.

Eligibility criteria:
inclusion criteria: * chronic upper extremity motor deficit due to multiple sclerosis exclusion criteria: * relapse within 3 months of planned enrollment.

Keywords: multiple sclerosis
radiofrequency ablation of atrial fibrillation under totally thoracoscope

Conditions: Atrial Fibrillation

Summary: atrial fibrillation (af) is a common supraventricular arrhythmia, the incidence of which increases with age. the aim of treatment of atrial fibrillation is to restore sinus rhythm and return the heart to atrioventricular synchrony, avoiding the risk of thromboembolism. the fact that pharmacological therapy of af is at best 50% effective has led to a search for surgical approaches over the last 20 years. maze procedure was a classic method to treat af. however, it is such a complex procedure that very few surgeons have adopted it. a few minimally invasive procedures to create transmural lesions which mimic maze procedure have been introduced. one of the mostly favored methods is catheter-based radiofrequency ablation, another one is video assisted epicardial radiofrequency ablation through small thoracic incisions in operating room. recently, we invented an epicardial radiofrequency ablation method under totally thoracoscope, which further minimized the surgery trauma and increased the cosmetic effect.


Eligibility criteria:
inclusion criteria: * any patients with atrial fibrillation exclusion criteria: * patients with hemostasis defects * patients can not endure general anesthesia

Keywords: atrial fibrillation radiofrequency totally thoracoscope epicardial
influence of diagnostic errors on the prognosis of acute pulmonary embolism

Conditions: Pulmonary Embolism; Pulmonary Embolism and Thrombosis; Diagnostic Errors; Embolism; Pulmonary Vascular Disorder

Summary: diagnostic errors have been reported frequently in patient with pulmonary embolism since symptoms are not specific. however, there is only scarce evidence that the delay associated with diagnostic errors may impact patient prognosis. the aim of this study is to determine the frequency of diagnostic errors and if they are associated with more severe pulmonary embolism in term of initial presentation and complications.


Eligibility criteria:
inclusion criteria: * 18 years and older * episode of symptomatic acute pulmonary embolism objectively proven exclusion criteria: * below 18 years of age * patient chronically receiving therapeutic anticoagulation * pulmonary embolism complicating a current hospitalisation for another medical reason * asymptomatic pulmonary embolism
efficacy and safety of non-invasive ventilation by calibrated leak in the treatment of respiratory acidosis in icu

Conditions: Respiratory Acidosis in ICU Patients

Summary: vni versus is a clinical, prospective, randomized, cross over study, aiming to compare two mechanical ventilators during non-invasive ventilation for patient suffering from respiratory acidosis. this study will compare a dedicated ventilator for non invasive ventilation (niv) functioning with a turbine and with vented mask (exhalation by a calibrated leak) and a dedicated ventilator for intensive care unit (icu), functioning with non-vented masks and an exhalation valve. patient will be randomized before the first niv session lasting 2 hours. after a two hours wash-out, a second niv treatment will be delivered with the other ventilator for duration of 2 hours. arterial blood samples will be collected at the beginning and the end of each session of niv. a transcutaneous captor of dioxide carbon pressure (pco2) will also be used for patient monitoring.


Eligibility criteria:
inclusion criteria: * dioxide carbon arterial pressure \> 60 mmhg * blood acidity (ph) \<7.36 exclusion criteria:-patient age under 18 * pregnant woman * cognitive disorder (other than the one induced by hypercapnia) * acute intoxication with morphine or benzodiazepines * patient already equipped prior to admission with a home niv or continuous positive airway pressure (cpap) device * all contraindications to niv already described in the french consensus conference on niv, from 2006.

Keywords: non-invasive ventilation niv ventilator exhalation by a calibrated leak icu ventilator respiratory acidosis icu
pilot trial: comparing buzzy to intradermal lidocaine for peripheral iv cannulation in adults

Conditions: Pain, Acute; Patient Satisfaction

Summary: iv placement is necessary for surgical procedures. unfortunately, some patients say that placing an iv is painful. the investigators are conducting this study to evaluate two techniques that could make the placement of the iv more comfortable.

currently, some medical providers administer the iv without any pain-relieving techniques. some medical providers inject a numbing medication underneath the skin prior to the iv placement. this requires an additional needle stick. some medical providers place a device called buzzy® on a patient's arm prior to the iv placement. the buzzy® device is the combination of an ice pack and a vibrator in the shape of a bumble bee. literature shows that the buzzy® device makes iv placement more comfortable for children, but there is minimal data in regard to whether it is helpful for adult patients. the investigators are conducting this study to compare the effectiveness of the buzzy® device with that of the injection of numbing medication underneath the skin for iv placement in adults. this device has been fda approved for use.

Eligibility criteria:
inclusion criteria: 1. adults ages 18 to 99 2. non-pregnant women and men 3. adults that are able to consent 4. patients requiring intravenous catheter insertion for their operation/procedure exclusion criteria: -
behavior enhances drug reduction of incontinence (be-dri)

Conditions: Urinary Incontinence (UI)

Summary: the primary aim of this study is to test if the addition of behavioral treatment to drug therapy for the treatment of urge incontinence will increase the number of patients who can discontinue drug therapy and sustain a significant reduction of incontinence.


Eligibility criteria:
inclusion: * female * urge predominant incontinence * incontinent \> 3 mos * available for 8 mos of followup exclusion: * pregnancy or \< 6 mos post-partum * hypersensitivity to drug (tolterodine) * systemic disease that affects bladder function (e.g., parkinson's disease, multiple sclerosis, spinal cord injury) * history of extensive behavior treatment

Keywords: urge urinary incontinence (uui) drug/behavior treatment
8mm-tips versus endoscopic variceal ligation (evl) plus propranolol for prevention of variceal rebleeding

Conditions: Portal Hypertension

Summary: the aim of this study was to conduct a prospective randomized trial to compare tips with 8mm expanded polytetrafluoroethylene(eptfe)-covered stents and endoscopic variceal ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding.

for the prevention of recurrent esophageal variceal bleeding, previous clinical studies and meta-analysis show that patients treated with transjugular intrahepatic portosystemic shunt (tips) have lower rebleeding rates compared with endoscopic therapy. however, tips is associated with higher rates of portosystemic encephalopathy and does not show survival benefit. tips with a small-diameter may achieve sufficient portal decompression and reduce the incidence of hepatic encephalopathy. the aim of this study was to conduct a prospective randomized trial to compare tips with 8mm eptfe-covered stents and endoscopic variceal ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding.

Eligibility criteria:
inclusion criteria: 1. cirrhosis 2. patients who had bled from esophageal varices (≥5days and ≤28days) 3. child-pugh b or child-pugh c≤13 exclusion criteria: 1. the presence of gastric varices 2. non-cirrhotic portal hypertension 3. portal vein thrombosis 4. the history of hepatic encephalopathy 5. total bilirubin ≥51.3 umol/l 6. previous treatment of tips or surgery 7. proven malignancy including hepatocellular carcinoma 8. contraindications to tips、evl or propranolol 9. end-stage renal disease under renal replacement therapy; 10. cardiorespiratory failure 11. pregnancy or patients not giving informed consent for endoscopic procedures
comparison of lotrafilcon b lenses with different packaging solutions

Conditions: Refractive Error

Summary: the purpose of this study is to evaluate air optix® plus hydraglyde® (aohg) contact lenses compared to air optix® aqua (aoa) contact lenses in overall lens fit.

subjects must not wear any contact lenses prior to the visit on day 1 (insertion) for period 1 or day 1 (insertion) for period 2.

Eligibility criteria:
inclusion criteria: * must sign informed consent document; * manifest cylinder less than or equal to 0.75 diopter (d) in each eye; * successful current wearer (during the past 2 months for a minimum of 5 days per week and 8 hours per day) of aoa contact lenses within the protocol-specified power range; * willing to answer text messages on a daily basis during the study; * willing to discontinue artificial tears and rewetting drops on the days of study visits; * other protocol-specified inclusion criteria may apply. exclusion criteria: * habitual lens wear in an extended wear modality (routinely sleeping in lenses overnight for 1 night per week); * any anterior segment infection, inflammation, disease or abnormality that contraindicates contact lens wear (within 7 days of enrollment, or current); * history of herpetic keratitis, corneal surgery or irregular cornea; * any use of systemic or ocular medications for which contact lens wear could be contraindicated; * monocular (only 1 eye with functional vision) or fit with only 1 lens; * pregnant or lactating; * participation in any clinical study within 30 days of visit 1; * other protocol-specified exclusion criteria may apply.
secondary prophylaxis gastric variceal bleed

Conditions: Cirrhosis

Summary: the investigators conducted a randomized, controlled trial (rct) to study the efficacy of beta blockers versus endoscopic cyanoacrylate injection in the prevention of gastric variceal (gov2 or igv1) rebleeding and improvement in survival.


Eligibility criteria:
inclusion criteria: * patients with gov2 without esophageal varix or igv1, who had bled from gv were included exclusion criteria: * presence of esophageal varix * gov2 with gov1; contraindications to beta-blocker therapy and cyanoacrylate injection * prior injection of cyanoacrylate or sclerotherapy for gv or gv ligation, transjugular intrahepatic portosystemic shunt, balloon-occluded retrograde transvenous obliteration, balloon-occluded endoscopic injection sclerotherapy of gv, shunt operation for prevention of rebleeding from gv * patients already on beta-blocker or nitrates * undetermined origin of bleeding from esophageal varix or gastric varix * hepatic encephalopathy grade iii/iv * hepatorenal syndrome * hepatocellular carcinoma * presence of deep jaundice (serum bilirubin \> 10 mg/dl) * uremia * cerebrovascular accident * cardiorespiratory failure * pregnancy or patients not giving informed consent for endoscopic procedures
study of computer-based treatment for drug dependence

Conditions: Opioid-Related Disorders; Heroin Dependence

Summary: the purpose of this study is to evaluate the whether an automated telephone-based system is useful and helpful for opioid dependent patients receiving buprenorphine in primary care. the recovery line support system is a therapeutic interactive voice response system based on cognitive behavioral therapy (cbt). the recovery line support system includes a variety of modules presenting the basic principles and strategies of cbt. each module includes learning sections and activities sections to provide direct guidance in using skills. the recovery line support system is interactive and also includes a questionnaire to help patients identify problems and recommend modules for use, as well as an inspiration section, an introduction, and an immediate assistance menu. following development of an initial system the current trial will recruit 40 patients receiving buprenorphine maintenance from a physician provider in the local community. patients will be randomly (flip of a coin) to receive the recover line support system or to treatment as usual with their physician. patients assigned to tivr will be trained on the system and provided 24-hr access to the tivr system for a four week period. primary outcome variables will be how long patients remain in treatment, self-reported abstinence from opioids and other drugs, and abstinence as measured by weekly drug screens. it is expected that patients assigned to tivr will better treatment outcomes than patients assigned to tau.


Eligibility criteria:
inclusion criteria: * are at least 18 years old * have initiated buprenorphine maintenance treatment from an approved physician in the previous two weeks exclusion criteria: * are a current suicide or homicide risk or meet criteria for psychiatric disorder that would interfere with ability to complete study * are unable to read or understand english * have a life-threatening or unstable medical problem

Keywords: interactive voice response computer-based treatment opioid agonist buprenorphine methadone
a study of cdx-585 in patients with advanced malignancies

Conditions: Non-small Cell Lung Cancer; Gastric Cancer; Head and Neck Cancer; Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer; Bladder Urothelial Carcinoma; Colorectal Cancer; Esophageal Cancer; Hepatic Cancer; Renal Cell Carcinoma; Cholangiocarcinoma; Pancreatic Cancer; Other Solid Tumors

Summary: this is an open-label, non-randomized, multicenter, dose-escalation and expansion study in patients with selected solid tumors.

this study will determine the maximum tolerated dose of cdx-585 while also evaluating the safety, tolerability, and efficacy of cdx-585 in patients with cancer. eligible patients that enroll to the dose-escalation portion of the study will be assigned to one of several dose levels of cdx-585. the dose-escalation part of the study will test the safety profile of cdx-585 and determine which dose of cdx-585 will be studied in the expansion portions of the study. all patients enrolled in the study will be closely monitored to determine if there is a response to the treatment as well as for any side effects that may occur. the expansion portion of the study will further evaluate the safety of cdx-585 in selected tumor types at the dose level chosen during the escalation part of the study.

Eligibility criteria:
key inclusion criteria: 1. recurrent, locally advanced, or metastatic solid tumor cancer excluding primary central nervous system tumors (e.g., glioblastoma). 2. receipt of standard therapy for the tumor type in the recurrent, locally advanced, or metastatic setting. 3. measurable (target) disease by irecist. 4. if of childbearing potential (male or female), agrees to practice an effective form of contraception during study treatment and for at least 3 months following last treatment. 5. willingness to undergo a pre-treatment and on-treatment biopsy, if required. key exclusion criteria: 1. history of severe hypersensitivity reactions to other monoclonal antibodies. 2. previous treatment with any anti-ilt4 antibody. 3. patients who have received more than 1 anti-pd-1 or anti-pd-l1 targeted therapy, including in the adjuvant setting. 4. prior anti-pd-l1 based therapy within 12 weeks and prior anti-pd-1 based therapy within four weeks to the planned start of study treatment. 5. other prior malignancy, except for adequately treated basal or squamous cell skin cancer or in situ cancers. for all other cancers, the patient must be disease-free for at least one year to be allowed to enroll. 6. thrombotic events within the last six months prior to study treatment 7. active, untreated central nervous system metastases. 8. active autoimmune disease or documented history of autoimmune disease. 9. history of (non-infectious) pneumonitis or has current pneumonitis. there are additional criteria your study doctor will review with you to confirm eligibility.

Keywords: lilrb2 cd85d ilt-4 pd1 bi-specific immunotherapy solid tumor malignancies dose escalation immunological
a novel intertransverse plane block: a magnetic resonance imaging and volunteer study

Conditions: Intertransverse Process Block; Thoracic Nerve Block; Thoracic Paravertebral Block

Summary: intertransverse process block (itpb) is a thoracic nerve block technique where the la is injected into the thoracic "intertransverse tissue complex" posterior to the superior costotransverse ligament (sctl). it may be an attractive alternative to a tpvb for unilateral surgery on the thorax, when considering the risk for pleural puncture, since it does not require direct needle access to the thoracic paravertebral space. however, although itpb is ultrasound guided, the la is frequently injected using surrogate bony landmarks in the sagittal sonogram, and in most cases without even identifying the sctl.

the knowledge regarding the spread of local anesthetic is a major prerequisite for a safe and effective use of all regional anesthetic methods in clinical practice. the primary outcome is the spread of injectate which will be evaluated on axial three-dimensional mri with contrast medium. the secondary outcome is the sensory dermatomal blockade of this novel itpb block.

Eligibility criteria:
inclusion criteria: * healthy thai men with no diseases exclusion criteria: * inability to cooperate or communicate in thai * bmi ≥ 30 kg/m2 or body weight ≤ 45 kgs * allergy to local anesthetics or contrast agents * infection in the block area * previous surgery or anatomical abnormalities of thoracic spines closed to block area * coagulation disorder/thrombocytopenia/anticoagulation therapy * contraindications to magnetic resonance imaging (mri) (metal implants - pacemaker and others, claustrophobia)

Keywords: mri study volunteer study
first episode psychosis and pathway to care in nordland

Conditions: First Episode Psychosis

Summary: first episode psychosis patients often experiences treatment delay. this reduces their prospects for recovery and makes unnecessary burdens for them and their carers. a better understanding of help seeking intentions is required, and has not been explored in a county like nordland, norway, with long distances and challenging access to health services. the purpose of this study is to explore the process of help seeking, including how patients and their careers discover and understand the psychotic symptoms. research exploring the impact on families mainly focuses on parents' experiences, and there are less studies focusing on experiences and needs of siblings. this study will therefore explore siblings' experiences separate from their parents. methods will be qualitative interviews with patients, their carers and siblings. analysis will be influenced by grounded theory.


Eligibility criteria:
inclusion criteria: * age 16-35, * understand and speak norwegian * able to give consent * no learning disabilities exclusion criteria: